In what could be a starting point for new therapeutics to tackle insulin resistance, a major driver of type 2 diabetes and metabolic syndrome present in 20–30 percent of the general U.S. population, researchers recently found that insulin resistance in the general population seems likely to be caused by a series of cell-specific signaling defects, some of which appear to be sex specific.